Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wumei Pill decoction is a traditional Chinese medicine (TCM) herbal formula being evaluated for the treatment of primary open-angle glaucoma (POAG). Developed and studied by the Eye Hospital, Chinese Academy of Chinese Medical Sciences, the decoction is based on the classic "Wumei Wan" formula, which traditionally includes Mume Fructus, Coptidis Rhizoma, and Aconiti Lateralis Radix Praeparata, among other herbs. In clinical research (ChiCTR2200062634), it is investigated for its ability to regulate 24-hour intraocular pressure (IOP) fluctuations and circadian rhythms. The treatment aims to stabilize visual function and mood by modulating circadian biomarkers such as cortisol and melatonin, potentially offering a systemic approach to glaucoma management beyond conventional IOP-lowering eye drops.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wumei pill decoction.